Visibility Vol 11 Issue 3 & 4, 2017


Effect of Fluocinolone Acetonide 0.2μg/day (ILUVIEN®) Implant on the Decision to Drive in Patients with Diabetic Macular Edema


The NEI-VFQ questionnaire was administered as part of the FAME phase 3 clinical trials. The driving subscale score (DSS), one of 12 subscale scores derived from the questionnaire, assesses driving difficulty in patients . The fluocinolone acetonide (FAc) 0.2μg/day implant is the only approved treatment for DME that continuously delivers therapy for 36 months with a single administration. This post hoc analysis was conducted to assess the relationship between improvement in visual acuity associated with 0.2μg/day FAc implant treatment and changes in the DSS over time and factors that may contribute to these findings.

Read More
photo of

Assessment of online patient education materials designed for people with age-related macular degeneration

Jennifer Fortuna, PhD, OTR/L; Linda Shuster, PhD, CCC-SLP, F-ASHA; Anne Riddering, PhD, OTR/L, CLVT, COMS; Cassie Lopez-Jeng, PhD, MPH, CPH, CHES

View Article
photo of

Minding the Gap: Determining Causes for Missed Low Vision Referrals to Develop a Streamlined, Sustainable Low Vision Rehabilitation System in Wisconsin

Katherine Dalzotto MD; Mark Banghart MS; Christina Thomas-Virnig PhD; Sanbrita Mondal OD

View Article
photo of

Assessment of Modified Patient Education Materials for People with Age-Related Macular Degeneration

Jennifer Fortuna, PhD, OTR/L; Linda Shuster, PhD, CCC-SLP, F-ASHA; Anne Riddering, PhD, OTR/L, CLVT, COMS; Cassie Lopez-Jeng, PhD; MPH, CPH, CHES

View Article